公开(公告)号：US20210164994A1

公开(公告)日：2021-06-03

申请号：US17045344

申请日：2019-04-02

Applicant: KONINKLIJKE PHILIPS N.V.

Inventor： Gerben KOOIJMAN ,  Michael Alex VAN HARTSKAMP ,  Amir Hussein RMAILE ,  Carl GLASSE ,  Philip PRESHAW ,  John TAYLOR ,  Iain Leslie Campbell CHAPPLE ,  Melissa Mackay GRANT ,  Marinus Karel Johannes DE JAGER

IPC: G01N33/68

Abstract: Disclosed is an in vitro method for assessing or predicting the response of a human patient to treatment of periodontal disease. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva of a patient, the concentrations are measured of certain protein combinations. One such combination is Alpha-1-acid glycoprotein (A1AGP) and at least one of Interleukin-1-beta (I-1β) and 5 Matrix metalloproteinase-8 (MMP-8). Based on the concentrations as measured, at least one value is determined reflecting the joint concentrations for said proteins. This at least one value may indicate the probability that human patient has been or will be successfully treated for the periodontitis. The at least one value can be compared with at least one threshold value reflecting in the same manner the joint concentrations associated with successful treatment of 10 periodontitis. The comparison allows assessing whether the testing value is indicative of the periodontal treatment status in said patient.

公开(公告)号：US20210132083A1

公开(公告)日：2021-05-06

申请号：US17046361

申请日：2019-04-10

Applicant: KONINKLIJKE PHILIPS N.V.

Inventor： Gerben KOOIJMAN ,  Michael Alex VAN HARTSKAMP ,  Amir Hussein RMAILE ,  Carl GLASSE ,  Marinus Karel Johannes DE JAGER ,  Philip PRESHAW ,  John TAYLOR ,  Iain Leslie Campbell CHAPPLE ,  Melissa Mackay GRANT

IPC: G01N33/68

Abstract: Disclosed is an in vitro method for assessing or predicting the response of a human patient to treatment of periodontal disease. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva of a patient, the concentrations are measured of certain protein combinations. One such combination is Hemoglobin subunit delta (Hb-delta) and Pyruvate kinase (PK). Another such combination is Keratin-4 (K-4) and at least two of Alpha-1-acid glycoprotein (A1AGP), Pyruvate Kinase (PK) and Matrix metalloproteinase-8 (MMP-8). A third combination is Alpha-1-acid glycoprotein (A1AGP), Pyruvate Kinase (PK) and S100 calcium binding protein A8 (S100A8). Based on the concentrations as measured, at least one value is determined reflecting the joint concentrations for said proteins. This at least one value may indicate the probability that human patient has been or will be successfully treated for the periodontitis. The at least one value can be compared with at least one threshold value reflecting in the same manner the joint concentrations associated with successful treatment of periodontitis. The comparison allows assessing whether the testing value is indicative of the periodontal treatment status in said patient.